Cardiff Oncology, Inc. (CRDF)

Over the past six months, Cardiff Oncology's stock price has experienced a decline. Positive Phase 2 CRDF-004 trial updates were reported in January 2026. Leadership changes occurred with CEO and CFO departures in January 2026, followed by key leadership appointments in April 2026. The company reported its Q4 2025 and Q3 2025 earnings. Clinical data from an investigator-sponsored Phase 1 trial evaluating onvansertib monotherapy in CMML were presented at ASH 2025. Preclinical data on onvansertib were presented at the AACR Annual Meeting 2026. An inducement equity grant was reported in April 2026.

As a clinical-stage biotechnology company, Cardiff Oncology's products are in the development phase and not yet commercially available, so there is no current demand seasonality. The demand for its product, onvansertib, is currently driven by the progress and outcomes of its clinical trials and the unmet medical needs in the cancer indications it targets.

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancer patients, operating within the Healthcare sector and Biotechnology industry. The company leverages PLK1 inhibition to address tumor vulnerabilities and treatment resistance. Their lead product candidate, onvansertib, is being evaluated in combination with standard-of-care therapeutics across various clinical programs, including RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple-negative breast cancer, and Chronic Myelomonocytic Leukemia. Other product candidates include CY140 and TROV-053.

Cardiff Oncology, Inc. primarily operates in the United States, with its headquarters in San Diego, California. The company conducts clinical trials across multiple sites in the United States and internationally.

Cardiff Oncology's brand reputation is primarily shaped by its clinical trial progress and scientific presentations. Positive data from the CRDF-004 trial in first-line RAS-mutated mCRC has been a significant positive. The departure and subsequent appointments of key leadership could have raised some questions, but the new appointments likely helped to stabilize and potentially enhance confidence in the company's direction. Presentations of preclinical data further bolster its scientific credibility.

The ownership structure of Cardiff Oncology stock includes individual investors holding approximately 60% and institutional investors owning about 38%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Laurion Capital Management LP, and Pfizer Inc.